Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients — NIMES-ROC

Relapsed Ovarian Cancer Clinical Trial

Official title:
NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug

Status Completed

Clinical Trial Summary

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02825420
Study type	Observational
Source	PharmaMar
Contact
Status	Completed
Phase
Start date	July 28, 2015
Completion date	September 18, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01874353` - Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Phase 3
Not yet recruiting	`NCT06081595` - Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment	Phase 2
Recruiting	`NCT04517357` - A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients	Phase 2
Recruiting	`NCT04887961` - Reprab Study: PLD + Trabectedin Rechallenge	Phase 2
Active, not recruiting	`NCT03534453` - Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Phase 3
Recruiting	`NCT05080556` - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer	Phase 2
Recruiting	`NCT05607329` - Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	N/A
Terminated	`NCT04999605` - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	Phase 1/Phase 2
Recruiting	`NCT04713514` - OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC	Phase 2
Not yet recruiting	`NCT05479487` - Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment	Phase 2